Market Intelligence, Clinical Progress, and High-Purity Reagents for Thrombosis, Hemostasis, and Rare Bleeding Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Coagulation Factor II (F2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | F2 Recombinant Protein (WT & G20210A Mutant), High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation, Zymogen Conformation). | View F2 Products |
| Gene Delivery | F2 Promise-ORF / Lentivirus, Full-length ORF for hepatocyte stable cell lines, codon-optimized. | View F2 Products |
| Benchmark Ab | Anti-F2 Control/Neutralizing Antibody, Recombinant positive control for binding, activity, and neutralization assays. | View F2 Products |
| Validator | F2 siRNA Set, For knockdown and specificity verification in cell-based assays. | View F2 Products |
| Related Target A | Coagulation Factor X (F10) – Upstream protease in prothrombinase complex; essential for F2 activation assays and synergistic pathway node. | View F10 Products |
| Related Target B | Coagulation Factor XI (F11) – Upstream regulator and next-generation safer anticoagulant target. | View F11 Products |
| Related Target C | Protease-Activated Receptor 1 (F2R/PAR-1) – Thrombin receptor for downstream signaling studies. | View F2R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Accurate Inhibitor Screening | High purity (>95%), Sequence Verified Recombinant F2 Proteins (WT & Mutant). |
| Genetic Variant Differentiation (G20210A) | Sequence-verified G20210A mutant protein for thrombophilia research and diagnostic calibration. |
| Zymogen vs Active Thrombin Discrimination | WT and Active Site Mutant (S195A) Proteins available; high purity for conformation-specific binding studies. |
| Off-Target Specificity (Vitamin K-dependent factors) | Homolog panel proteins (F7, F9, F10, F11) strictly verified by mass spec and theoretical MW. |
| Lack of Standardized Controls & False Positives | Clinical Benchmark Antibodies and validated siRNA included for specificity checks; chromogenic substrate compatible. |
Live Coagulation Factor II R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for Coagulation Factor II (Prothrombin/Thrombin) is well-established but continuously evolving. Small molecule direct thrombin inhibitors (DTIs/DOACs) like dabigatran and argatroban dominate anticoagulation therapy, while current R&D focuses on developing rapid reversal agents (e.g., Idarucizumab), dual-pathway inhibitors, and formulations with improved safety profiles. As first-generation therapies mature, the next wave of innovation targets refined therapeutic windows to balance hemostasis and thrombosis. In parallel, the market is witnessing a strategic pivot towards safer anticoagulation reversal agents, enzyme replacement therapies for rare congenital prothrombin deficiency, and precision medicine diagnostics (e.g., G20210A variant screening). Selective zymogen-targeting antibodies that block thrombin generation rather than active thrombin activity are emerging as a potential strategy to reduce bleeding risk.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (DTIs/DOACs) | Boehringer Ingelheim, Novartis, Mitsubishi Tanabe | Atrial Fibrillation, DVT, Stroke prevention | Selectivity Assay (Need High-Purity F2 vs F10/F11 proteins, WT & Mutant). |
| Reversal Agents/Antidotes | Boehringer Ingelheim (Idarucizumab)* | Bleeding Emergencies | Binding Affinity & Antigen Specificity (Need sequence verified target and off-target panel). |
| Peptide / Aptamer | Various Biotechs | Surgical Hemostasis | High-concentration stability test (Endotoxin Controlled). |
| Enzyme Replacement | Rare disease biotechs | Congenital Prothrombin Deficiency | Activity Assay (Need native folded zymogen; Endotoxin controlled). |
| Diagnostic Kits | Roche, Abbott | Thrombophilia screening | Immunoassay Standards (Sequence-verified WT and G20210A mutant). |
*Idarucizumab targets the anticoagulant drug, not F2 itself; F2 antigen is critical for specificity screening of such agents.